Ryegonovin en es it fr

Ryegonovin Brand names, Ryegonovin Analogs

Ryegonovin Brand Names Mixture

  • No information avaliable

Ryegonovin Chemical_Formula


Ryegonovin RX_link


Ryegonovin fda sheet

Ryegonovin msds (material safety sheet)

Ryegonovin MSDS

Ryegonovin Synthesis Reference

A. Stoll et al., eidem, Helv. Chim. Acta. 26, 944 (1943)

Ryegonovin Molecular Weight

339.432 g/mol

Ryegonovin Melting Point

172 oC

Ryegonovin H2O Solubility

25 mg/mL

Ryegonovin State


Ryegonovin LogP


Ryegonovin Dosage Forms

Injection (intramuscular or intravenous); Tablet

Ryegonovin Indication

For the prevention and control of excessive bleeding following vaginal childbirth

Ryegonovin Pharmacology

Methylergonovine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.

Ryegonovin Absorption

Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.

Ryegonovin side effects and Toxicity

Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.

Ryegonovin Patient Information

Ryegonovin Organisms Affected

Humans and other mammals